Author:
Alousi Amin M.,Boinpally Ramesh,Wiegand Richard,Parchment Ralph,Gadgeel Shirish,Heilbrun Lance K.,Wozniak Antionette J.,DeLuca Pamela,LoRusso Patricia M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference19 articles.
1. Polin L, White K, Kushner J, Paluch J, Simpson C, Pugh S et al (2002) Preclinical efficacy evaluations of XK-469: dose schedule, route and cross-resistance behavior in tumor bearing mice. Invest New Drugs 20(1):13–22
2. Corbett TH, LoRusso P, Demchick L, Simpson C, Pugh S, White K et al (1998) Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate. Invest New Drugs 16(2):129–139
3. Ding Z, Parchment RE, LoRusso PM, Zhou JY, Li J, Lawrence TS et al (2001) The investigational new drug XK469 induces G(2)-M cell cycle arrest by p53-dependent and -independent pathways. Clin Cancer Res 7(11):3336–3342
4. Gao H, Huang KC, Yamasaki EF, Chan KK, Chohan L, Snapka RM (1999) XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci USA 96(21):12168–12173
5. Snapka RM, Gao H, Grabowski DR, Brill D, Chan KK, Li L et al (2001) Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I. Biochem Biophys Res Commun 280(4):1155–1160
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献